Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives. Founded in 1989 in Cambridge, MA, Vertex today has research and development sites and commercial offices around the world in the United States, Canada, Europe and Australia. Read more about our global locations.
In May 2011, the U.S. Food and Drug Administration (FDA) approved Vertex’s first medicine, a treatment for hepatitis C. In 2012, Vertex received approval for our medicine for cystic fibrosis in the U.S., Europe and Canada. Vertex received Australian approval of our medicine for cystic fibrosis in 2013. Read more about our approved medicines.
In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Read more about our pipeline.
We collaborate with some of the world’s largest pharmaceutical companies, leading nonprofit disease foundations and many of the world’s best-known academic institutions. Read more about our collaborations.
Vertex has continually been recognized as one of the industry’s top workplaces by leading publications such as Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Read more about our recognition and awards.